Analyst consensus rating
ARS Pharmaceuticals Analyst Rating: Strong Buy
SPRY is rated Strong Buy by 4 analysts with a $23.25 target. As of 2026-08-22.
Direct answer
ARS Pharmaceuticals's consensus rating is Strong Buy.
4 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $23.25.
Forecast evidence checked August 22, 2026.
Get free ARS Pharmaceuticals email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $5.51
- Average price target
- $23.25
- High price target
- $30.00
- Low price target
- $17.00
- Low target gap
- +208.8%
- Target upside
- +322.3%
- High target gap
- +445%
- Target range width
- 236.1%
- Consensus rating
- Strong Buy
- Analysts
- 4
- Evidence date
- August 22, 2026
- Valid through
- August 29, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for ARS Pharmaceuticals?
ARS Pharmaceuticals has a verified Strong Buy consensus. The same dataset has an average price target of $23.25.
How far are ARS Pharmaceuticals's low and high targets from the recorded price?
The low target implies +208.8%, while the high target implies +445%.
How many analysts are included in ARS Pharmaceuticals's consensus?
The verified consensus includes 4 analysts.
How is ARS Pharmaceuticals's target upside or downside calculated?
The average target of $23.25 is divided by the recorded price of $5.51, then one is subtracted to produce +322.3%. This does not guarantee a future return.
When was ARS Pharmaceuticals's analyst forecast verified?
The data was verified on 2026-08-22. The dataset is valid through 2026-08-29.